Update: AstraZeneca U.S. data vaccine has 76 percent overall efficacy
Interim data published on Monday had put the vaccine's efficacy rate at 79 percent but had not included more recent infections, leading to a highly unusual public rebuke from US health officials.
AstraZeneca also reiterated that the shot, developed with Oxford University, was 100 percent effective against severe or critical forms of the disease. There have been eight severe cases – all among trial participants who received the placebo.
The latest data was based on 190 infections among more than 32,400 participants in the United States, Chile and Peru. The earlier interim data was based on 141 infections through February 17.
It also said the vaccine showed 85 percent efficacy in adults 65 years and older, higher than the 80 percent rate reported on Monday. ■